Immobilization of Angiogenic Peptides in Mesenchymal Stem Cell Membrane for Liver Fibrosis Attenuation via Ex-vivo Cell Surface Engineering
발표자
()
초록
내용
Placenta-derived mesenchymal stem cells (PDMSCs) offer great potential for treating liver fibrosis due to their high therapeutic ability to hepatocytes. To enhance PDMSCs’ ability, we employed biomaterial-based ex vivo cell surface engineering. Therapeutic peptides (WKYMVm) with specific affinity toward formyl protein receptor 2 were decorated onto PDMSC surfaces using lipid-PEG conjugates via hydrophobic interaction, for inducing angiogenesis and tissue repair. Co-delivery of therapeutic peptides with PDMSCs could effectively attenuate liver fibrosis in damaged liver. Activation of neighboring PDMSCs as well as recovery of damaged hepatocytes could be subsequently achieved without excessive use of peptides. Our in vitro and in vivo results demonstrated that surface-engineered PDMSCs facilitated superior angiogenesis and recovery as compared to naïve PDMSCs. Overall, our study highlights the potential of peptide-based stem cell surface engineering as a powerful approach for liver treatment.